#galaxysurfactants #Q3investorpresentations

:Q2 momentum spilled into Q3
:Speciality segment double digit growth
:Domestic mkt double digit growth
:Interim dividend Rs 14

Vols Q3fy21/20
Performance surfactants 36618/34978
Speciality 21620/19295
Total 58238/54273

Revenue HLs
Q3fy21/20 in crs
Performance surfactants 401/387
Speciality 277/242
Total 678/629
PAT 85/48

9mnths fy21 vols
India mkt up 13.3%
Africa & ME Up 6.3%
ROW down -10.1%

9mnth FHs in cr
PS 1292/1187
Speciality 717/759
Total 2009/1946
PAT 223/168
Truly Indian MNC
:Leading mftr of ingredients for home & personal care industry
:preferred supplier for MNC,Regional & local Fmcg
:205+ product grades
: 7 strategic facilities (5 India,1Egypt ,1 US)
: Extensive R&D capacity
: intellectual property- 78 approved,1e applied
1750+ clients
80+ countries
1550+ employees

India's largest mftr of Oleochemical based surfactants & specialty care products for home & personal care

Focus - personal & home care (hair,oral,home,skin,cosmetics,toiletries)
Performance surfactants- Anionic & Non-ionic

Speciality care products - Amphoteric ,Cationic ,UV Filters ,preservatives, speciality ingredients ,fatty alkanolamides & fatty acid esters

Rev mix performance(mainly fmcg) vs speciality(oligopolistic player) 64/36%
Clients - HUL, Dabur ,P&G ,Colgate ,Reckitt, Himalaya ,Emami ,L'oreal, Henkel

Fy20 rev :
MNC 55%
Regional 11
Local & niche 34
Multiple awards from clients - Gold award for its Innovative product TiLS(G) - oil soluble surfactant ,great place to work
Rev in crs
Fy15 1875
Fy20 2602

Ebidta
Fy15 192
Fy20 375

PAT
Fy15 68
Fy20 230

Ebidta per tonne
Fy15 12518
Fy20 16716

Vol growth
Fy15 153374
Fy20 224237

D/E
Fy15 1.1
Fy20 0.4

ROE
Fy15 20.4
Fy20 24.7%

CFO
FY15 41
FY20 316

ROCE
Fy15 18.6
Fy20 23.5%
#galaxysurfactants #Q3marketupdates
Q3 FY21 Cons
Total vol up 7.3% yoy Revenue 677Cr, up 7.7% yoy
EBITDA 122.5 Cr, up 43.3% yoy driven by increasing share of specialty, better product mix & higher capacity utilization PAT 85.2 Cr up 77.6% yoy
Interim Dividend 14Rs
#Q3marketupdates #Q3investorpresentations #Q3updates

Unroll
@threadreaderapp
Compile
@threader_app

#galaxysurfactants #Nifty #stocks

More from India

Some readers have been asking what #India2030 is all about.
Here’s a chapter-by-chapter thread on the 20 forecasts by 20 thought leaders on 20 themes that will define India in the 2020s.
1/n


Chapter 20 of #India2030 by @davidfrawleyved talks about how the Civilizational Resurgence of India will reconnect its ancient past to ride into a dharmic future
2/n

Chapter 19 of #India2030 by @devdip tells us what the new idea of Nationalism in the 2020s will be — an integral union of the nation with the self
3/n

Chapter 18 of #India2030 by @sandipanthedeb examines how ideologies and technologies will intrude into and redefine Friendships
4/n

Chapter 17 of #India2030 by @authoramish studies the Soft Power of India and says its global influence will be through the confluence of materialism and spiritualism
5/n

You May Also Like

@franciscodeasis https://t.co/OuQaBRFPu7
Unfortunately the "This work includes the identification of viral sequences in bat samples, and has resulted in the isolation of three bat SARS-related coronaviruses that are now used as reagents to test therapeutics and vaccines." were BEFORE the


chimeric infectious clone grants were there.https://t.co/DAArwFkz6v is in 2017, Rs4231.
https://t.co/UgXygDjYbW is in 2016, RsSHC014 and RsWIV16.
https://t.co/krO69CsJ94 is in 2013, RsWIV1. notice that this is before the beginning of the project

starting in 2016. Also remember that they told about only 3 isolates/live viruses. RsSHC014 is a live infectious clone that is just as alive as those other "Isolates".

P.D. somehow is able to use funds that he have yet recieved yet, and send results and sequences from late 2019 back in time into 2015,2013 and 2016!

https://t.co/4wC7k1Lh54 Ref 3: Why ALL your pangolin samples were PCR negative? to avoid deep sequencing and accidentally reveal Paguma Larvata and Oryctolagus Cuniculus?